TITLE:
Cholangiocarcinoma in Patients with Crohn’s Disease
AUTHORS:
Tarek Debs, Isabella Reccia, Imad El-Hajj, Ziad El-Rassi
KEYWORDS:
Cholangiocarcinoma, Crohn’s, Inflammatory Bowel Disease, Infliximab
JOURNAL NAME:
Journal of Cancer Therapy,
Vol.6 No.1,
December
26,
2014
ABSTRACT: Cholangiocarcinoma
is an uncommon malignancy that increases with age. Cholangiocarcinoma has been
linked to inflammatory bowel disease, and a relationship between inflammatory
bowel disease, anti-tumour necrosis factor alpha antibody (Infliximab) and
cholangiocarcinoma has been suggested. Although cholangiocarcinoma is usually
associated with ulcerative colitis, recently more cases are being seen in association
with Crohn’s disease. The risk of cancer in patients treated with Infliximab
has been discussed, and whether Infliximab is associated with an increased risk
of cholangiocarcinoma is not clear. Cholangiocarcinoma is an uncommon
malignancy and it is difficult to establish a clear correlation with Infliximab
treatment. A large number of reports are needed to further address these
issues.